MX368972B - Composiciones de glicoproteínas sialiladas y usos de estas. - Google Patents

Composiciones de glicoproteínas sialiladas y usos de estas.

Info

Publication number
MX368972B
MX368972B MX2016011416A MX2016011416A MX368972B MX 368972 B MX368972 B MX 368972B MX 2016011416 A MX2016011416 A MX 2016011416A MX 2016011416 A MX2016011416 A MX 2016011416A MX 368972 B MX368972 B MX 368972B
Authority
MX
Mexico
Prior art keywords
glycoprotein compositions
sialylated glycoprotein
sialylated
compositions
disorders
Prior art date
Application number
MX2016011416A
Other languages
English (en)
Other versions
MX2016011416A (es
Inventor
Steven Jungles
Morris Gabrielle
Grubb Jeff
Vellard Michael
D Kakkis Emil
Original Assignee
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultragenyx Pharmaceutical Inc filed Critical Ultragenyx Pharmaceutical Inc
Publication of MX2016011416A publication Critical patent/MX2016011416A/es
Publication of MX368972B publication Critical patent/MX368972B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente solicitud se relaciona con composiciones de glicoproteínas sialiladas y sus métodos de uso en el tratamiento de varias afecciones o trastornos.
MX2016011416A 2014-03-05 2015-03-05 Composiciones de glicoproteínas sialiladas y usos de estas. MX368972B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461948421P 2014-03-05 2014-03-05
US201562114313P 2015-02-10 2015-02-10
PCT/US2015/018859 WO2015134696A1 (en) 2014-03-05 2015-03-05 Sialylated glycoprotein compositions and uses thereof

Publications (2)

Publication Number Publication Date
MX2016011416A MX2016011416A (es) 2016-12-02
MX368972B true MX368972B (es) 2019-10-23

Family

ID=54016314

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016011416A MX368972B (es) 2014-03-05 2015-03-05 Composiciones de glicoproteínas sialiladas y usos de estas.

Country Status (17)

Country Link
US (7) US9457067B2 (es)
EP (1) EP3113781B1 (es)
JP (1) JP6581590B2 (es)
KR (1) KR102150481B1 (es)
CN (1) CN106102749B (es)
AU (1) AU2015227137B2 (es)
BR (1) BR112016019893B1 (es)
CA (1) CA2940318C (es)
ES (1) ES2704923T3 (es)
IL (1) IL247550B (es)
MX (1) MX368972B (es)
MY (1) MY188028A (es)
PE (1) PE20161417A1 (es)
PH (1) PH12016501658A1 (es)
RU (1) RU2689119C2 (es)
TW (1) TWI702049B (es)
WO (1) WO2015134696A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2704923T3 (es) 2014-03-05 2019-03-20 Ultragenyx Pharmaceutical Inc Composiciones de glicoproteínas sialiladas y usos de las mismas
EP3724314A1 (en) 2017-12-13 2020-10-21 3M Innovative Properties Company Water-reconstitutable culture medium resistant to liquefaction by microorganisms
TWI667252B (zh) * 2018-07-13 2019-08-01 中原大學 阿伐-選擇性唾液酸供體及其於製備唾液酸苷的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
SI1543106T1 (sl) * 2002-07-15 2007-08-31 Immunex Corp Postopki in mediji za nadziranje sialilacije proteinov, ki jih proizvajajo sesalske celice
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
ES2387028T3 (es) * 2003-12-31 2012-09-12 Merck Patent Gmbh Proteína de fusión de Fc-eritropoyetina con farmacocinética mejorada
EP1818395A1 (en) * 2006-02-08 2007-08-15 Diatos Compositions and methods for treating lysosomal storage diseases
ES2620261T3 (es) * 2006-09-10 2017-06-28 Glycotope Gmbh Uso de células humanas de origen leucémico mieloide para expresión de anticuerpos
WO2008109677A2 (en) * 2007-03-06 2008-09-12 Saint Louis University Modified enzyme and treatment method
WO2011096750A2 (en) * 2010-02-08 2011-08-11 Korea Advanced Institute Of Science And Technology Method for preparing recombinant glycoproteins with high sialic acid content
WO2012101671A1 (en) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
KR101457514B1 (ko) * 2011-11-21 2014-11-03 한국생명공학연구원 우렁쉥이(멍게) 유래의 시알산 전이효소 및 이를 이용한 시알화 복합당질 합성 방법
US10138474B2 (en) * 2012-08-17 2018-11-27 Research Foundation Of The City University Of New York Scavenger receptor uptake for fabry disease enzyme replacement therapy
ES2704923T3 (es) 2014-03-05 2019-03-20 Ultragenyx Pharmaceutical Inc Composiciones de glicoproteínas sialiladas y usos de las mismas

Also Published As

Publication number Publication date
PH12016501658A1 (en) 2016-10-03
US9937243B2 (en) 2018-04-10
US20160367646A1 (en) 2016-12-22
IL247550A0 (en) 2016-11-30
MX2016011416A (es) 2016-12-02
US20150250860A1 (en) 2015-09-10
CN106102749A (zh) 2016-11-09
IL247550B (en) 2020-10-29
EP3113781B1 (en) 2018-11-21
ES2704923T3 (es) 2019-03-20
RU2016138790A3 (es) 2018-08-23
AU2015227137A1 (en) 2016-09-15
US9457068B2 (en) 2016-10-04
KR20160127124A (ko) 2016-11-02
US9687532B2 (en) 2017-06-27
JP6581590B2 (ja) 2019-09-25
EP3113781A1 (en) 2017-01-11
US9457067B2 (en) 2016-10-04
CA2940318A1 (en) 2015-09-11
WO2015134696A1 (en) 2015-09-11
US20190054153A1 (en) 2019-02-21
RU2689119C2 (ru) 2019-05-24
BR112016019893B1 (pt) 2023-02-14
PE20161417A1 (es) 2017-01-22
CA2940318C (en) 2020-09-22
MY188028A (en) 2021-11-10
CN106102749B (zh) 2019-07-12
US20150366951A1 (en) 2015-12-24
TW201615210A (zh) 2016-05-01
US20170326210A1 (en) 2017-11-16
AU2015227137B2 (en) 2019-06-06
US20220202915A1 (en) 2022-06-30
KR102150481B1 (ko) 2020-09-02
TWI702049B (zh) 2020-08-21
BR112016019893A2 (pt) 2017-10-24
US20200282028A1 (en) 2020-09-10
JP2017508455A (ja) 2017-03-30
RU2016138790A (ru) 2018-04-09
EP3113781A4 (en) 2017-08-09

Similar Documents

Publication Publication Date Title
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
WO2016029191A3 (en) Channel modulators
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
HK1243325A1 (zh) 用於治療視覺障礙的組合物和方法
JO3343B1 (ar) أحماض 5- أمينوتتراهيدروكوينولين-2- كربوكسيليك جديدة واستخدامها
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EP3160493A4 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
PH12018500659A1 (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
PH12017500836A1 (en) Transdermal formulations
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
PH12016500495A1 (en) Compositions for the treatment of hypertension and/or fibrosis
MY177827A (en) Combination of valerian root extract and lavender oil for use in the treatment of sleep disorders
PH12016501658A1 (en) Sialylated glycoprotein compositions and uses thereof
MX2018007468A (es) Composiciones de colageno 7 y metodos para usar las mismas.
MY182818A (en) Compositions for the treatment of fibrosis and fibrosis-related conditions
MX2015008947A (es) Nuevas composiciones antifungicas.
MX2017014893A (es) Composicion herbal para el tratamiento del dolor de espalda.
MA39718A (fr) Compositions et méthodes d'utilisation de celles-ci
TH1501005684A (th) จุลชีพรีคอมบิแนนท์ที่มีความสามารถในการผลิต 2,3-บิวเทนไดออลที่เพิ่มขึ้น และ วิธีการสำหรับการผลิต 2,3-บิวเทนไดออลโดยการใช้สิ่งเดียวกันนี้

Legal Events

Date Code Title Description
FG Grant or registration